Scientific Presentation with Prof. John Bartlett reviewing the current data on Molecular Profiling from prognosis to prediction.
There is robust evidence for predictive value using gene expression profiles to direct chemotherapy choices in the neo-adjuvant and adjuvant setting
The use of prognostic signatures to predict chemotherapy benefit means that many of the existing challenges of these prognostic signatures will also impact on predictive use.
Gaps in evidence exist particularly for pre-menopausal women with ovarian suppression and clinically very high risk (pN2 patients)
Discrepancies in test results at the individual patient level give rise for concern.
The impact of other variables is uncertain at present (e.g. Lobular cancers, Male breast cancer, ethnicity)